These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 21198858

  • 41. [Progress of study on survivin in diffuse large B-cell lymphoma--review].
    Dou HJ, Hu JP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1487-90. PubMed ID: 19099670
    [Abstract] [Full Text] [Related]

  • 42. ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.
    Wu J, He Z, Zhu Y, Jiang C, Deng Y, Wei B.
    Curr Cancer Drug Targets; 2021 Dec; 21(1):80-89. PubMed ID: 32933462
    [Abstract] [Full Text] [Related]

  • 43. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling.
    Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS.
    J Pathol; 2010 Oct; 222(2):180-90. PubMed ID: 20632385
    [Abstract] [Full Text] [Related]

  • 44. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.
    Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ, Oudejans JJ.
    Blood; 2008 Jan 01; 111(1):369-75. PubMed ID: 17916749
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. [Expression of Apoptosis-related Protein Livin and Caspase-3 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].
    Jin L, Sui YX, Chen ZZ, Li YH, Wang LP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec 01; 25(6):1664-1669. PubMed ID: 29262894
    [Abstract] [Full Text] [Related]

  • 47. Subcellular localization of X-linked inhibitor of apoptosis protein (XIAP) in cancer: Does that matter?
    Mendonça BS, Ferreira CA, Maia RC, Nestal de Moraes G.
    BBA Adv; 2022 Dec 01; 2():100050. PubMed ID: 37082602
    [Abstract] [Full Text] [Related]

  • 48. Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.
    Papageorgiou SG, Thomopoulos TP, Katagas I, Bouchla A, Pappa V.
    Ther Adv Hematol; 2021 Dec 01; 12():20406207211013987. PubMed ID: 34104369
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer.
    He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, Zhu S, Chen X, Yang C, Gao H.
    Int J Clin Exp Pathol; 2014 Dec 01; 7(2):742-50. PubMed ID: 24551298
    [Abstract] [Full Text] [Related]

  • 53. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
    Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P, Al-Kuraya KS.
    Haematologica; 2012 Jul 01; 97(7):1092-100. PubMed ID: 22271891
    [Abstract] [Full Text] [Related]

  • 54. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic B, Mihaljevic B.
    Eur J Haematol; 2011 Mar 01; 86(3):246-55. PubMed ID: 21198858
    [Abstract] [Full Text] [Related]

  • 55. c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
    Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Filipovic B, Radovanović S, Zdravković M, Stanisavljevic D, Mihaljevic B.
    Biomed Pharmacother; 2013 Jun 01; 67(5):445-9. PubMed ID: 23582793
    [Abstract] [Full Text] [Related]

  • 56. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 57. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 58. Standard treatment of advanced-stage diffuse large B-cell lymphoma.
    Coiffier B.
    Semin Hematol; 2006 Oct 20; 43(4):213-20. PubMed ID: 17027655
    [Abstract] [Full Text] [Related]

  • 59. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O, Marisavljevic D, Cemerikic V, Perunicic M, Savic S, Filipovic B, Mihaljevic B.
    Eur J Haematol; 2011 Mar 20; 86(3):246-55. PubMed ID: 21198858
    [Abstract] [Full Text] [Related]

  • 60. c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
    Markovic O, Marisavljevic D, Cemerikic-Martinovic V, Filipovic B, Radovanović S, Zdravković M, Stanisavljevic D, Mihaljevic B.
    Biomed Pharmacother; 2013 Jun 20; 67(5):445-9. PubMed ID: 23582793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.